| melanoma

Mektovi vs Tecentriq

Side-by-side clinical, coverage, and cost comparison for melanoma.

Deep comparison between: Mektovi vs Tecentriq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecentriq has a higher rate of injection site reactions vs Mektovi based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecentriq but not Mektovi, including UnitedHealthcare

Category

Mektovi

Tecentriq

At A Glance

RouteOral

FrequencyTwice daily

ClassMEK inhibitor

RouteIV infusion

FrequencyEvery 2-4 weeks

ClassPD-L1 antagonist

Indications

melanoma
Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Carcinoma
Small cell carcinoma of lung
Liver carcinoma
Melanoma
Alveolar Soft Part Sarcoma

Dosing

melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.

Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.

Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.

Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.

Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.

Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.

Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.

Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.

Contraindications

—

Drug Interactions

1022View drug interactions

189View drug interactions

Adverse Reactions

Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough

Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion

Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).

Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.

Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.

Pharmacology

Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.

Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Mektovi